Agentix's Losses Widen Amid Cash Crunch, Going Concern Doubts Mount

TL;DR

**AGTX is burning cash with widening losses and a 'going concern' warning; stay away until they prove they can fund operations.**

AI Summary

Agentix Corp. (AGTX) reported a net loss of $144,107 for the three months ended September 30, 2025, a 58.9% increase from the $90,669 net loss in the same period of 2024. For the six months ended September 30, 2025, the net loss widened to $329,931, up from $241,386 in 2024. Total operating expenses increased to $123,097 for the three months ended September 30, 2025, compared to $93,010 in 2024, driven by a significant rise in research and development costs to $25,079 from $11,850. The company's cash position remains critically low at $5,601 as of September 30, 2025, down from $100,274 in total current assets as of March 31, 2025, and it continues to operate with a substantial accumulated deficit of $6,851,459. AGTX also reported negative cash flows from operating activities of $115,367 for the six months ended September 30, 2025, and a negative working capital, raising substantial doubt about its ability to continue as a going concern without further funding.

Why It Matters

This filing reveals Agentix Corp. is in a precarious financial state, with widening losses and minimal cash, directly impacting investor confidence and the company's ability to fund its clinical-stage biotechnology development. For employees, the going concern warning signals potential job insecurity. Customers and the broader market, particularly those interested in metabolic disease treatments like Type 2 diabetes, obesity, NAFLD, and NASH, face uncertainty regarding the future of AGTX's therapeutic agents, potentially shifting competitive dynamics if AGTX cannot secure funding to advance its pipeline.

Risk Assessment

Risk Level: high — The company explicitly states 'These factors raise substantial doubt about the Company's ability to continue as a going concern.' Cash on hand is critically low at $5,601 as of September 30, 2025, and it has an accumulated deficit of $6,851,459, indicating severe financial distress and a high risk of insolvency.

Analyst Insight

Investors should exercise extreme caution and avoid investing in AGTX given the explicit 'going concern' warning, widening losses, and minimal cash reserves. Current shareholders should consider divesting, as the company's ability to fund its operations and advance its pipeline is highly questionable without significant, immediate external financing.

Financial Highlights

total Assets

$5,601

net Income

-$144,107

eps

-$0.00

cash Position

$5,601

Key Numbers

• $5,601 — Cash on hand (as of September 30, 2025, down from $4,477 in March 2025, indicating critically low liquidity.)
• $144,107 — Net loss for Q3 2025 (increased from $90,669 in Q3 2024, showing widening operational losses.)
• $329,931 — Net loss for six months ended Sept 30, 2025 (increased from $241,386 in the prior year, reflecting a growing accumulated deficit.)
• $6,851,459 — Accumulated deficit (as of September 30, 2025, indicating significant historical losses.)
• $115,367 — Net cash used in operating activities (for the six months ended September 30, 2025, highlighting negative operational cash flow.)
• 40,066,951 — Shares of common stock outstanding (as of November 19, 2025, indicating the current share count.)
• $123,097 — Total operating expenses for Q3 2025 (increased from $93,010 in Q3 2024, driven by R&D.)
• $25,079 — Research and development expenses for Q3 2025 (increased from $11,850 in Q3 2024, a 111.6% rise.)

Key Players & Entities

• Agentix Corp. (company) — registrant of the 10-Q filing
• SEC (regulator) — Securities and Exchange Commission
• FairWind Energy, Inc. (company) — former name of Agentix Corp.
• GSL Healthcare, Inc. (company) — wholly owned subsidiary of Agentix Corp.
• AB Merger LLC (company) — wholly owned subsidiary of Agentix Corp.
• Agentix Australia Pty Ltd (company) — wholly owned subsidiary of Agentix Corp.
• Applied Biopharma (company) — wholly owned subsidiary of Agentix Corp.
• Nevada (other) — state of incorporation for Agentix Corp.

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: Agentix Corp. faces substantial doubt about its ability to continue as a going concern. As of September 30, 2025, the company had only $5,601 in cash and a total current asset balance of $5,601, a significant decrease from $100,274 in March 2025. The company also reported negative operating cash flow of $115,367 for the six months ended September 30, 2025, and a substantial accumulated deficit of $6,851,459.
• Increasing Net Losses [high — financial]: The company's net losses are widening. For the three months ended September 30, 2025, the net loss was $144,107, a 58.9% increase from $90,669 in the prior year. The six-month net loss also increased to $329,931 from $241,386 in the same period of 2024.
• Rising Operating Expenses [medium — operational]: Total operating expenses increased by 32.3% to $123,097 for the three months ended September 30, 2025, compared to $93,010 in the prior year. This increase was primarily driven by a significant 111.6% rise in research and development expenses, which more than doubled from $11,850 to $25,079.
• Negative Working Capital [high — financial]: Agentix Corp. has negative working capital, with total current liabilities of $3,423,639 as of September 30, 2025, significantly exceeding its total current assets of $5,601. This indicates a short-term liquidity challenge.
• High Related Party Payables [medium — financial]: The company has substantial accounts payable to related parties ($2,258,947 as of September 30, 2025) and a note payable to a related party ($343,350). These balances represent a significant portion of current liabilities.

Industry Context

Agentix Corp. operates in a sector that often requires significant R&D investment, leading to high operating expenses and potential for extended periods of unprofitability. The competitive landscape likely demands continuous innovation, putting pressure on companies to fund development activities. However, the current economic climate and investor sentiment towards early-stage or struggling biotech/tech firms can make securing additional capital challenging.

Regulatory Implications

As a publicly traded company, Agentix Corp. must adhere to SEC reporting requirements, including timely filing of 10-Q and 10-K reports. The company's financial distress and going concern warnings may attract increased scrutiny from regulators and investors regarding its financial reporting and future viability.

What Investors Should Do

1. Monitor cash burn rate and future funding announcements.
2. Analyze the sustainability of R&D spending.
3. Evaluate the company's ability to secure additional financing.
4. Assess the risk associated with related party transactions.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported a net loss of $144,107 and cash on hand of $5,601, highlighting deteriorating financial condition and going concern risks.
• 2025-03-31: End of Fiscal Year 2025 — Reported total current assets of $100,274, indicating a significant decline in liquidity by Q3 2025.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income or other gains. (Agentix Corp. has a substantial accumulated deficit of $6,851,459 as of September 30, 2025, indicating significant historical unprofitability.)

Going concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. (The company's financial condition raises substantial doubt about its ability to continue as a going concern, necessitating further funding.)

Working capital

The difference between a company's current assets and current liabilities. It indicates short-term financial health. (Agentix Corp. has negative working capital, signaling potential difficulties in meeting short-term obligations.)

Operating expenses

Costs incurred by a company in its normal business operations, excluding costs of goods sold. (Agentix Corp. saw a significant increase in operating expenses, particularly in R&D, contributing to wider net losses.)

Research and development (R&D) expenses

Costs incurred by a company for research and development activities aimed at creating new products or improving existing ones. (A sharp rise in R&D expenses for Agentix Corp. is a key driver of increased operating costs and net losses.)

Year-Over-Year Comparison

Compared to the prior year, Agentix Corp. has experienced a significant deterioration in its financial performance. For the three months ended September 30, 2025, the net loss increased by 58.9% to $144,107, and total operating expenses rose by 32.3% to $123,097, largely due to a substantial increase in R&D costs. The company's cash position has become critically low, falling to $5,601 from $100,274 in total current assets between March 31, 2025, and September 30, 2025, underscoring a worsening liquidity situation and increased going concern risks.

Key Financial Figures

• $0.001 — were 40,066,951 shares of common stock, $0.001 par value per share, outstanding. AGEN

Filing Documents

• agtx_10q.htm (10-Q) — 438KB
• agtx_ex311.htm (EX-31.1) — 13KB
• agtx_ex312.htm (EX-31.2) — 13KB
• agtx_ex321.htm (EX-32.1) — 5KB
• 0001477932-25-008502.txt ( ) — 1734KB
• agtx-20250930.xsd (EX-101.SCH) — 16KB
• agtx-20250930_lab.xml (EX-101.LAB) — 111KB
• agtx-20250930_cal.xml (EX-101.CAL) — 25KB
• agtx-20250930_pre.xml (EX-101.PRE) — 84KB
• agtx-20250930_def.xml (EX-101.DEF) — 28KB
• agtx_10q_htm.xml (XML) — 153KB

Financial Information

Part I. Financial Information Item 1.

Financial Statements

Financial Statements F-1 Consolidated Balance Sheets at September 30, 2025 (Unaudited) and March 31, 2025 (Audited). F-1 Unaudited Consolidated Statements of Operations for the three and six months ended September 30, 2025 and 2024. F-2 Unaudited Consolidated Statements of Changes in Stockholders' Deficit for the three and six months ended September 30, 2025 and 2024. F-3 Unaudited Consolidated Statements of Cash Flows for the six months ended September 30, 2025 and 2024. F-4

Notes to Financial Statements (Unaudited)

Notes to Financial Statements (Unaudited). F-5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 4 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 6 Item 4.

Controls and Procedures

Controls and Procedures. 6

Other Information

Part II. Other Information Item 1. Legal Proceedings. 7 Item 1A.

Risk Factors

Risk Factors 7 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 7 Item 3. Defaults Upon Senior Securities. 7 Item 4. Mine Safety Disclosures. 7 Item 5. Other Information. 7 Item 6. Exhibits. 8

Signatures

Signatures 9 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q of Agentix Corp., a Nevada corporation (the "Company"), contains "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "could", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: the Company's need for and ability to obtain additional financing, product demand, market and customer acceptance, competition, public health crises, pricing and development difficulties, as well as general industry and market conditions and growth rates, general economic conditions, and other factors over which we have little or no control; and other factors discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Our management has included projections and estimates in this Form 10-Q, which are based primarily on management's experience in the industry, assessments of our results of operations, dis

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS. Agentix Corp. and Subsidiaries Consolidated Balance Sheets September 30, 2025 March 31, 2025 (Unaudited) Assets Current Assets Cash $ 5,601 $ 4,477 Prepaid expense and other current assets - 95,797 Total current assets 5,601 100,274 Total assets $ 5,601 $ 100,274 Liabilities and Stockholders' Deficit Current Liabilities Accounts payable $ 711,639 $ 968,888 Accounts payable - related parties 2,258,947 1,932,438 Note payable - related party 343,350 243,000 Accrued expenses 109,703 60,197 Total current liabilities 3,423,639 3,204,523 Long Term Liabilities - - Total liabilities 3,423,639 3,204,523 Commitments and Contingencies - - Stockholders' Deficit Common stock par value $ 0.001 : 50,000,000 shares authorized; 40,066,951 shares issued and outstanding as of September 30, 2025 and March 31, 2025, respectively 40,067 40,067 Common stock to be issued ( 357,102 at September 30, 2025 and March 31, 2025, respectively) 53,535 53,535 Additional paid-in capital 3,288,296 3,288,296 Accumulated other comprehensive income 51,523 35,381 Accumulated deficit ( 6,851,459 ) ( 6,521,528 ) Total stockholders' deficit ( 3,418,038 ) ( 3,104,249 ) Total liabilities and stockholders' deficit $ 5,601 $ 100,274 See accompanying notes to the unaudited consolidated financial statements. F-1 Table of Contents Agentix Corp. and Subsidiaries Unaudited Consolidated Statements of Operations Three Months Three Months Six Months Six Months Ended Ended Ended Ended September 30, September 30, September 30, September 30, 2025 2024 2025 2024 Operating Expenses Professional fees $ 81,233 $ 64,310 $ 163,858 $ 141,310 Research and development 25,079 11,850 125,079 67,351 General and administrative expenses 16,785 16,850 34,502 35,654 Total operating expenses 123,097 93,010 323,439

View Full Filing

View this 10-Q filing on SEC EDGAR